AVIDITY BIOSCIENCES INC (RNA) Stock Fundamental Analysis
NASDAQ:RNA - Nasdaq - US05370A1088 - Common Stock - Currency: USD
Taking everything into account, RNA scores 4 out of 10 in our fundamental rating. RNA was compared to 563 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RNA as it has an excellent financial health rating, but there are worries on the profitability. RNA shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year RNA has reported negative net income.
RNA had a negative operating cash flow in the past year.
In the past 5 years RNA always reported negative net income.
RNA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -20.61%, RNA is doing good in the industry, outperforming 78.51% of the companies in the same industry.
The Return On Equity of RNA (-22.62%) is better than 84.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.61% | ||
| ROE | -22.62% | ||
| ROIC | N/A |
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RNA has been increased compared to 1 year ago.
The number of shares outstanding for RNA has been increased compared to 5 years ago.
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
RNA has an Altman-Z score of 14.45. This indicates that RNA is financially healthy and has little risk of bankruptcy at the moment.
RNA's Altman-Z score of 14.45 is amongst the best of the industry. RNA outperforms 91.83% of its industry peers.
RNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 14.45 |
ROIC/WACCN/A
WACC10.1%
2.3 Liquidity
A Current Ratio of 15.73 indicates that RNA has no problem at all paying its short term obligations.
With an excellent Current ratio value of 15.73, RNA belongs to the best of the industry, outperforming 91.47% of the companies in the same industry.
RNA has a Quick Ratio of 15.73. This indicates that RNA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of RNA (15.73) is better than 91.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.73 | ||
| Quick Ratio | 15.73 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.34% over the past year.
RNA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.95%.
The Revenue has been growing by 36.26% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)0.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.27%
Revenue 1Y (TTM)13.95%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%35.57%
3.2 Future
Based on estimates for the next years, RNA will show a very strong growth in Earnings Per Share. The EPS will grow by 27.40% on average per year.
RNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 168.92% yearly.
EPS Next Y-36.18%
EPS Next 2Y-24.45%
EPS Next 3Y0.5%
EPS Next 5Y27.4%
Revenue Next Year-26.63%
Revenue Next 2Y31.4%
Revenue Next 3Y228.41%
Revenue Next 5Y168.92%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
RNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.45%
EPS Next 3Y0.5%
5. Dividend
5.1 Amount
No dividends for RNA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
27.87
-0.82 (-2.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners107.03%
Inst Owner Change0.21%
Ins Owners0.89%
Ins Owner Change2.72%
Market Cap3.36B
Analysts82.35
Price Target68.18 (144.64%)
Short Float %13.7%
Short Ratio10.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.75%
Min EPS beat(2)-0.04%
Max EPS beat(2)9.54%
EPS beat(4)2
Avg EPS beat(4)6.83%
Min EPS beat(4)-0.83%
Max EPS beat(4)18.66%
EPS beat(8)5
Avg EPS beat(8)6.16%
EPS beat(12)8
Avg EPS beat(12)4.57%
EPS beat(16)10
Avg EPS beat(16)1.75%
Revenue beat(2)1
Avg Revenue beat(2)23.63%
Min Revenue beat(2)-45.8%
Max Revenue beat(2)93.05%
Revenue beat(4)2
Avg Revenue beat(4)15.25%
Min Revenue beat(4)-45.8%
Max Revenue beat(4)93.05%
Revenue beat(8)5
Avg Revenue beat(8)5.64%
Revenue beat(12)8
Avg Revenue beat(12)5.45%
Revenue beat(16)11
Avg Revenue beat(16)15.69%
PT rev (1m)0.39%
PT rev (3m)-1.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.87%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.95%
Revenue NQ rev (1m)-11.12%
Revenue NQ rev (3m)-3.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 308.24 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.36 | ||
| P/tB | 2.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.89
EYN/A
EPS(NY)-3.94
Fwd EYN/A
FCF(TTM)-2.56
FCFYN/A
OCF(TTM)-2.5
OCFYN/A
SpS0.09
BVpS11.82
TBVpS11.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.61% | ||
| ROE | -22.62% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-27.2%
ROA(5y)-24.5%
ROE(3y)-31.7%
ROE(5y)-28.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 254.54% | ||
| Cap/Sales | 64.84% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 15.73 | ||
| Quick Ratio | 15.73 | ||
| Altman-Z | 14.45 |
F-Score4
WACC10.1%
ROIC/WACCN/A
Cap/Depr(3y)219.55%
Cap/Depr(5y)307.52%
Cap/Sales(3y)46.55%
Cap/Sales(5y)39.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.27%
EPS Next Y-36.18%
EPS Next 2Y-24.45%
EPS Next 3Y0.5%
EPS Next 5Y27.4%
Revenue 1Y (TTM)13.95%
Revenue growth 3Y5.31%
Revenue growth 5Y36.26%
Sales Q2Q%35.57%
Revenue Next Year-26.63%
Revenue Next 2Y31.4%
Revenue Next 3Y228.41%
Revenue Next 5Y168.92%
EBIT growth 1Y-60.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-56.8%
EBIT Next 3Y6.26%
EBIT Next 5YN/A
FCF growth 1Y-149.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-152.7%
OCF growth 3YN/A
OCF growth 5YN/A